当前位置:首页>产品中心>单抗/多抗>Anti-Human PIP4K2A Polyclonal Antibody|抗人PIP4K2A多克隆抗体(靶标:人磷脂酰肌醇-5-磷酸4-激酶2A型)

Anti-Human PIP4K2A Polyclonal Antibody|抗人PIP4K2A多克隆抗体(靶标:人磷脂酰肌醇-5-磷酸4-激酶2A型)

  • 货号:RB9THD637014
  • 价格:面议
  • 点击:619
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human, Rat, Mouse
靶标1-phosphatidylinositol 5-phosphate 4-kinase 2-alpha, Diphosphoinositide kinase 2-alpha, EC:2.7.1.149, PI(5)P 4-kinase type II alpha, PI5P4KA, PI5P4Kalpha, PIP4K2A, PIP4KII-alpha, PIP5K2, PIP5K2A, PIP5
免疫原E. coli - derived recombinant Human PIP4K2A (Ser34-Thr406).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号P48426
背景信息

Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha (PIP4K2A) is a ~46 kDa protein. Catalyzes the phosphorylation of phosphatidylinositol 5-phosphate (PtdIns5P) on the fourth hydroxyl of the myo-inositol ring, to form phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). Has both ATP- and GTP-dependent kinase activities. May exert its function by regulating the levels of PtdIns5P, which functions in the cytosol by increasing AKT activity and in the nucleus signals through ING2. May regulate the pool of cytosolic PtdIns5P in response to the activation of tyrosine phosphorylation. Required for lysosome-peroxisome membrane contacts and intracellular cholesterol transport through modulating peroxisomal PtdIns(4,5)P2 level.

1. Davis, MI. et al. (2013) PloS one 8, e54127. PMID: 23326584
2. Rameh, LE. et al. (1997) Nature 390, 192-6. PMID: 9367159
3. Sumita, K. et al. (2016) Molecular cell 61, 187-98. PMID: 26774281
4. Wilcox, A. et al. (2008) FEBS letters 582, 1391-4. PMID: 18364242
5. Hu, A. et al. (2018) Journal of lipid research 59, 507-514. PMID: 29353240
6. Wang, DG. et al. (2019) Cell reports 27, 1991-2001.e5. PMID: 31091439
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 772
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 685
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 796
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 612
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 713
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 692
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 550
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 495
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 467
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 533
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 366
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 477
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 503
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 485
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 686
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 521
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 802
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 682
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 537
Anti-Sarilumab Non-Neutralizing Recombinant Antibody|抗萨瑞鲁单抗非中和重组抗体(靶标:萨瑞鲁单抗非中和抗体) 794
总计 33037 个记录,共 1652 页,当前第 1646 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30